1.
Indian J Ophthalmol
; 72(5): 617-619, 2024 May 01.
Article
in English
| MEDLINE
| ID: mdl-38661271
ABSTRACT
Bevacizumab is a monoclonal, humanized, full-length antibody targeting vascular endothelial growth factor(VEGF-A), known for its anti-angiogenic properties. The off-label use of bevacizumab has stirred legal, financial, industrial, and ethical complexities. With its potential to treat diverse ocular conditions, this commentary delves into the multifaceted dimensions of bevacizumab's off-label utilization, encompassing clinical trials, regulatory frameworks, safety considerations, comparative effectiveness, and economic implications.
Subject(s)
Angiogenesis Inhibitors , Antibodies, Monoclonal, Humanized , Bevacizumab , Intravitreal Injections , Off-Label Use , Vascular Endothelial Growth Factor A , Humans , Angiogenesis Inhibitors/administration & dosage , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Bevacizumab/administration & dosage , Bevacizumab/therapeutic use , Global Health , Vascular Endothelial Growth Factor A/antagonists & inhibitors
2.
Indian J Ophthalmol
; 72(2): 290-291, 2024 Feb 01.
Article
in English
| MEDLINE
| ID: mdl-38273687
3.
Indian J Ophthalmol
; 72(1): 136-138, 2024 Jan 01.
Article
in English
| MEDLINE
| ID: mdl-38131588
4.
Indian J Ophthalmol
; 71(6): 2602-2603, 2023 Jun.
Article
in English
| MEDLINE
| ID: mdl-37322692
